
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4266623/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<i>Asxl1</i> loss cooperates with oncogenic <i>Nras</i> in mice to reprogram the immune microenvironment and drive leukemic transformation. Blood, 2022, 139, 1066-1079.	1.4	24
2	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nature Biotechnology, 2022, 40, 499-506.	17.5	110
3	Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome. Blood, 2022, 139, 2038-2049.	1.4	34
4	Sex-Biased <i>ZRSR2</i> Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis. Cancer Discovery, 2022, 12, 522-541.	9.4	44
5	Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors. New England Journal of Medicine, 2022, 386, 735-743.	27.0	87
6	Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic. Genes and Development, 2022, 36, 259-277.	5.9	19
7	Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells. Nature Biotechnology, 2022, 40, 1103-1113.	17.5	24
8	ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1. Molecular Cell, 2022, 82, 2443-2457.e7.	9.7	9
9	Dysregulation and therapeutic targeting of RNA splicing in cancer. Nature Cancer, 2022, 3, 536-546.	13.2	65
10	Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Science Translational Medicine, 2022, 14, .	12.4	10
11	Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS/STING/NLRP3 axis in myelodysplastic syndromes. JCI Insight, 2022, 7, .	5.0	16
12	High frequency of clonal hematopoiesis in Erdheim-Chester disease. Blood, 2021, 137, 485-492.	1.4	30
13	U2af1 is required for survival and function of hematopoietic stem/progenitor cells. Leukemia, 2021, 35, 2382-2398.	7.2	21
14	Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway. Nature Communications, 2021, 12, 1826.	12.8	54
15	Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Advances, 2021, 5, 1552-1564.	5.2	102
16	Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition. Nature Genetics, 2021, 53, 707-718.	21.4	61
17	Molecular classification improves risk assessment in adult <i>BCR-ABL1–</i> negative B-ALL. Blood, 2021, 138, 948-958.	1.4	59
18	Histiocytosis and the nervous system: from diagnosis to targeted therapies. Neuro-Oncology, 2021, 23, 1433-1446.	1.2	33

#	Article	IF	CITATIONS
19	Splicing regulation in hematopoiesis. Current Opinion in Hematology, 2021, 28, 277-283.	2.5	2
20	Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. Molecular Cell, 2021, 81, 2183-2200.e13.	9.7	59
21	AXL Inhibition in Macrophages Stimulates Host-versus-Leukemia Immunity and Eradicates NaÃ ⁻ ve and Treatment-Resistant Leukemia. Cancer Discovery, 2021, 11, 2924-2943.	9.4	20
22	Splicing factor mutations in hematologic malignancies. Blood, 2021, 138, 599-612.	1.4	40
23	Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell, 2021, 184, 4032-4047.e31.	28.9	131
24	Histiocytosis. Lancet, The, 2021, 398, 157-170.	13.7	58
25	Therapeutic Modulation of RNA Splicing in Malignant and Non-Malignant Disease. Trends in Molecular Medicine, 2021, 27, 643-659.	6.7	36
26	Promoting spliceosome assembly for therapeutic intent. Trends in Pharmacological Sciences, 2021, 42, 981-983.	8.7	3
27	ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine. Blood Cancer Journal, 2021, 11, 157.	6.2	27
28	mRNA Export as a Novel Cancer-Specific Dependency. Cancer Discovery, 2021, 11, 2129-2131.	9.4	0
29	Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target. Leukemia, 2021, 35, 1037-1052.	7.2	19
30	Mutant SF3B1 promotes AKT- and NF-κB–driven mammary tumorigenesis. Journal of Clinical Investigation, 2021, 131, .	8.2	22
31	MAP-Kinase-Driven Hematopoietic Neoplasms: A Decade of Progress in the Molecular Age. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a034892.	6.2	17
32	Structural basis of cytokine-mediated activation of ALK family receptors. Nature, 2021, 600, 143-147.	27.8	20
33	Splicing-Mediated Antigen Escape from Immunotherapy for B-cell Malignancies. Blood Cancer Discovery, 2021, , .	5.0	4
34	SRSF2-P95Hdelays Myelofibrosis Development through Altered JAK/STAT Signaling in JAK2-V617F Megakaryocytes. Blood, 2021, 138, 2544-2544.	1.4	1
35	Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High-Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence. Blood, 2021, 138, 3753-3753.	1.4	1
36	High Throughput Single-Cell Simultaneous Genotyping and Chromatin Accessibility Reveals Genotype to Phenotype Relationship in Human Myeloproliferation. Blood, 2021, 138, 678-678.	1.4	1

#	Article	IF	CITATIONS
37	Single-Cell Multi-Omics Defines the Cell-Type Specific Impact of SF3B1 Splicing Factor Mutations on Hematopoietic Differentiation in Human Clonal Hematopoiesis and Myelodysplastic Syndromes. Blood, 2021, 138, 145-145.	1.4	3
38	First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl. Blood, 2021, 138, 43-43.	1.4	2
39	Modulation of RNA Splicing Enhances Response to BCL2 Inhibition in Acute Myeloid Leukemia. Blood, 2021, 138, 507-507.	1.4	5
40	Impaired RAS Proteolysis Drives Clonal Hematopoietic Transformation. Blood, 2021, 138, 356-356.	1.4	0
41	Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by <i>MAP2K1</i> . Haematologica, 2020, 105, e5-e8.	3.5	34
42	Hairy Cell Leukemia. , 2020, , 1872-1883.e5.		0
43	SnapShot: Splicing Alterations in Cancer. Cell, 2020, 180, 208-208.e1.	28.9	58
44	Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial. Lancet Haematology,the, 2020, 7, e566-e574.	4.6	13
45	Oncogenic splicing regulated by phase separation. Nature Cell Biology, 2020, 22, 916-918.	10.3	1
46	Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations. Blood, 2020, 135, 1032-1043.	1.4	11
47	Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. Cancer Cell, 2020, 38, 198-211.e8.	16.8	99
48	ABCA1 Exerts Tumor-Suppressor Function in Myeloproliferative Neoplasms. Cell Reports, 2020, 30, 3397-3410.e5.	6.4	18
49	DNA methylation disruption reshapes the hematopoietic differentiation landscape. Nature Genetics, 2020, 52, 378-387.	21.4	154
50	Leveraging Systematic Functional Analysis to Benchmark an <i>In Silico</i> Framework Distinguishes Driver from Passenger MEK Mutants in Cancer. Cancer Research, 2020, 80, 4233-4243.	0.9	18
51	Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms. Blood, 2020, 136, 1477-1486.	1.4	43
52	Genetic basis for iMCD-TAFRO. Oncogene, 2020, 39, 3218-3225.	5.9	14
53	Neurologic and oncologic features of Erdheim–Chester disease: a 30-patient series. Neuro-Oncology, 2020, 22, 979-992.	1.2	31
54	Recurrent SRSF2 mutations in MDS affect both splicing and NMD. Genes and Development, 2020, 34, 413-427.	5.9	44

#	Article	IF	CITATIONS
55	ZBTB1 Regulates Asparagine Synthesis and Leukemia Cell Response to L-Asparaginase. Cell Metabolism, 2020, 31, 852-861.e6.	16.2	40
56	Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim–Chester disease patients following BRAF inhibitor monotherapy. Neuro-Oncology Advances, 2020, 2, vdaa024.	0.7	7
57	Mutations in the RNA Splicing Factor SF3B1 Promote Tumorigenesis through MYC Stabilization. Cancer Discovery, 2020, 10, 806-821.	9.4	73
58	The Effect of SF3B1 Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in Cancer. Frontiers in Oncology, 2020, 10, 609409.	2.8	15
59	Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. Journal of Clinical Investigation, 2020, 130, 981-997.	8.2	146
60	Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. Journal of Clinical Investigation, 2020, 130, 6668-6676.	8.2	28
61	Male-Biased Spliceosome Mutations in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Impair pDC Activation and Apoptosis. Blood, 2020, 136, 13-14.	1.4	1
62	Venetoclax Therapy for Relapsed and Treatment Refractory AML: Clinical Outcomes and Molecular Predictors. Blood, 2020, 136, 47-48.	1.4	1
63	<i>ZRSR2</i> Mutation Induced Minor Intron Retention Drives MDS and Diverse Cancer Predisposition Via Aberrant Splicing of <i>LZTR1</i> . Blood, 2020, 136, 10-11.	1.4	1
64	Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia. Leukemia, 2019, 33, 390-402.	7.2	44
65	Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation. Cancer Cell, 2019, 36, 194-209.e9.	16.8	184
66	Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis. Cancer Discovery, 2019, 9, 1452-1467.	9.4	60
67	Somatic mutations and cell identity linked by Genotyping of Transcriptomes. Nature, 2019, 571, 355-360.	27.8	206
68	Altered RNA Processing in Cancer Pathogenesis and Therapy. Cancer Discovery, 2019, 9, 1493-1510.	9.4	106
69	Muscarinic acetylcholine receptor regulates self-renewal of early erythroid progenitors. Science Translational Medicine, 2019, 11, .	12.4	12
70	Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML. Cancer Discovery, 2019, 9, 872-889.	9.4	36
71	Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL. Nature Communications, 2019, 10, 1874.	12.8	63
72	Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. Molecular Cancer Therapeutics, 2019, 18, 1149-1157.	4.1	26

#	Article	IF	CITATIONS
73	Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature, 2019, 567, 521-524.	27.8	222
74	Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia. Cancer Cell, 2019, 35, 369-384.e7.	16.8	238
75	BRAF in the cross-hairs. Expert Review of Hematology, 2019, 12, 183-193.	2.2	0
76	A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease. Blood Advances, 2019, 3, 934-938.	5.2	17
77	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nature Medicine, 2019, 25, 1839-1842.	30.7	122
78	PTEN isoforms with dual and opposing function. Nature Cell Biology, 2019, 21, 1306-1308.	10.3	6
79	Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. Nature, 2019, 574, 273-277.	27.8	149
80	Spliceosomal disruption of the non-canonical BAF complex in cancer. Nature, 2019, 574, 432-436.	27.8	163
81	Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900. Haematologica, 2019, 104, e147-e150.	3.5	4
82	Aberrant RNA Splicing in Cancer. Annual Review of Cancer Biology, 2019, 3, 167-185.	4.5	73
83	First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl. Blood, 2019, 134, 3998-3998.	1.4	8
84	Spliceosomal Disruption of the Non-Canonical SWI/SNF Chromatin Remodeling Complex in SF3B1 Mutant Leukemias. Blood, 2019, 134, 637-637.	1.4	1
85	Aberrant RNA Splicing Contributes to the Pathogenesis of EVI-Rearranged Myeloid Leukemias. Blood, 2019, 134, 917-917.	1.4	0
86	Single-agent dabrafenib for <i>BRAF</i> ^{V600E} -mutated histiocytosis. Haematologica, 2018, 103, e177-e180.	3.5	40
87	Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. Cancer Discovery, 2018, 8, 648-661.	9.4	97
88	Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs. Stem Cell Reports, 2018, 10, 1610-1624.	4.8	43
89	Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation. Journal of Experimental Medicine, 2018, 215, 1729-1747.	8.5	113
90	H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nature Medicine, 2018, 24, 497-504.	30.7	391

#	Article	IF	CITATIONS
91	The Augmented R-Loop Is a Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing Factor Mutations. Molecular Cell, 2018, 69, 412-425.e6.	9.7	203
92	Editorial overview: Cancer genomics: RNA metabolism and translation in cancer pathogenesis and therapy. Current Opinion in Genetics and Development, 2018, 48, iv-vi.	3.3	4
93	Targeting mRNA Decapping in AML. Cancer Cell, 2018, 33, 339-341.	16.8	3
94	Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis. Pediatric Blood and Cancer, 2018, 65, e26699.	1.5	16
95	Vemurafenib for <i>BRAF</i> V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis. JAMA Oncology, 2018, 4, 384.	7.1	280
96	The histopathology of Erdheim–Chester disease: a comprehensive review of a molecularly characterized cohort. Modern Pathology, 2018, 31, 581-597.	5.5	102
97	Activating p53 and Inhibiting Superenhancers to Cure Leukemia. Trends in Pharmacological Sciences, 2018, 39, 1002-1004.	8.7	5
98	ProteomeGenerator: A Framework for Comprehensive Proteomics Based on de Novo Transcriptome Assembly and High-Accuracy Peptide Mass Spectral Matching. Journal of Proteome Research, 2018, 17, 3681-3692.	3.7	24
99	A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia. Cancer Research, 2018, 78, 6762-6770.	0.9	17
100	Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene <i>U2af1</i> . Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E10437-E10446.	7.1	59
101	KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function. Oncogene, 2018, 37, 4692-4710.	5.9	102
102	Stem Cell Model of Hematologic Diseases. , 2018, , 111-118.		0
103	Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. Cancer Cell, 2018, 34, 225-241.e8.	16.8	162
104	Cancer-Specific Splicing Changes and the Potential for Splicing-Derived Neoantigens. Cancer Cell, 2018, 34, 181-183.	16.8	38
105	Widespread intronic polyadenylation inactivates tumour suppressor genes in leukaemia. Nature, 2018, 561, 127-131.	27.8	172
106	Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. Journal of Clinical Investigation, 2018, 128, 3819-3825.	8.2	45
107	Histiocytoses: emerging neoplasia behind inflammation. Lancet Oncology, The, 2017, 18, e113-e125.	10.7	154
108	Splicing factor mutations in MDS RARS and MDS/MPN-RS-T. International Journal of Hematology, 2017, 105, 720-731.	1.6	16

#	Article	IF	CITATIONS
109	ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. Nature Communications, 2017, 8, 15429.	12.8	55
110	Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood, 2017, 130, 167-175.	1.4	136
111	Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. Blood, 2017, 130, 397-407.	1.4	112
112	Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms. Hematology/Oncology Clinics of North America, 2017, 31, 705-719.	2.2	20
113	Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. Blood, 2017, 130, 176-180.	1.4	98
114	Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood, 2017, 130, 410-423.	1.4	163
115	How do messenger RNA splicing alterations drive myelodysplasia?. Blood, 2017, 129, 2465-2470.	1.4	28
116	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood, 2017, 129, 553-560.	1.4	193
117	Molecular Pathways: Understanding and Targeting Mutant Spliceosomal Proteins. Clinical Cancer Research, 2017, 23, 336-341.	7.0	28
118	A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. Nature, 2017, 549, 389-393.	27.8	144
119	Modeling CBL activating mutations in vivo. Blood, 2017, 129, 2046-2048.	1.4	0
120	Therapeutic targeting of RNA splicing in myelodysplasia. Seminars in Hematology, 2017, 54, 167-173.	3.4	9
121	Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression. Cell, 2017, 170, 1079-1095.e20.	28.9	522
122	Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations. Blood, 2017, 130, 1644-1648.	1.4	82
123	High prevalence of myeloid neoplasms in adults with non–Langerhans cell histiocytosis. Blood, 2017, 130, 1007-1013.	1.4	98
124	The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Advances, 2017, 1, 357-366.	5.2	163
125	Splicing factor SF3B1K700E mutant dysregulates erythroid differentiation via aberrant alternative splicing of transcription factor TAL1. PLoS ONE, 2017, 12, e0175523.	2.5	24
126	Integrated Molecular Analysis Identifies Replicative Stress As Sensitizer to Imetelstat Therapy in AML. Blood, 2017, 130, 798-798.	1.4	2

#	Article	IF	CITATIONS
127	Partial loss of genes might open therapeutic window. ELife, 2017, 6, .	6.0	2
128	Oncogenic Mutations in <i>XPO1</i> Promote Lymphoid Transformation By Altering Nuclear/Cytoplasmic Localization of NFIºB Signaling Intermediates. Blood, 2017, 130, 879-879.	1.4	0
129	Characterization of Ntrk fusions and Therapeutic Response to Ntrk Inhibition in Hematologic Malignancies. Blood, 2017, 130, 794-794.	1.4	Ο
130	Histiocytic neoplasms in the era of personalized genomic medicine. Current Opinion in Hematology, 2016, 23, 416-425.	2.5	37
131	MSI2 is required for maintaining activated myelodysplastic syndrome stem cells. Nature Communications, 2016, 7, 10739.	12.8	27
132	Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nature Medicine, 2016, 22, 672-678.	30.7	301
133	Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis. Genes and Development, 2016, 30, 989-1001.	5.9	95
134	Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood, 2016, 127, 1551-1558.	1.4	105
135	Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood, 2016, 127, 3004-3014.	1.4	244
136	Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood, 2016, 127, 2451-2459.	1.4	198
137	Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood, 2016, 127, 2672-2681.	1.4	1,040
138	Modeling SF3B1 Mutations in Cancer: Advances, Challenges, and Opportunities. Cancer Cell, 2016, 30, 371-373.	16.8	24
139	Therapeutic targeting of splicing in cancer. Nature Medicine, 2016, 22, 976-986.	30.7	484
140	Genetic drivers of vulnerability and resistance in relapsed acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11071-11073.	7.1	9
141	Emerging concepts of epigenetic dysregulation in hematological malignancies. Nature Immunology, 2016, 17, 1016-1024.	14.5	77
142	Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia. British Journal of Haematology, 2016, 175, 402-409.	2.5	26
143	EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. Cancer Cell, 2016, 30, 197-213.	16.8	200
144	Loss of Asxl1 Alters Self-Renewal and Cell Fate of Bone Marrow Stromal Cells, Leading to Bohring-Opitz-like Syndrome in Mice. Stem Cell Reports, 2016, 6, 914-925.	4.8	18

#	Article	IF	CITATIONS
145	The Role of Additional Sex Combs-Like Proteins in Cancer. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a026526.	6.2	48
146	Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease. Blood, 2016, 128, 1896-1898.	1.4	24
147	Diffuse reduction of cerebral grey matter volumes in Erdheim-Chester disease. Orphanet Journal of Rare Diseases, 2016, 11, 109.	2.7	19
148	DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nature Medicine, 2016, 22, 1488-1495.	30.7	195
149	ASXL1 plays an important role in erythropoiesis. Scientific Reports, 2016, 6, 28789.	3.3	38
150	Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". Nature Medicine, 2016, 22, 578-579.	30.7	7
151	RNA splicing factors as oncoproteins and tumour suppressors. Nature Reviews Cancer, 2016, 16, 413-430.	28.4	549
152	Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development. Cancer Cell, 2016, 30, 92-107.	16.8	130
153	Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms. Leukemia and Lymphoma, 2016, 57, 1517-1526.	1.3	4
154	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discovery, 2016, 6, 154-165.	9.4	372
155	Unlike <i>ASXL1</i> and <i>ASXL2</i> mutations, <i>ASXL3</i> mutations are rare events in acute myeloid leukemia with t(8;21). Leukemia and Lymphoma, 2016, 57, 199-200.	1.3	19
156	Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study. Blood, 2016, 128, 480-480.	1.4	5
157	Synthetic Lethal Interactions of MDS-Associated Spliceosomal Gene Mutations Identifies the Basis for Their Mutual Exclusivity. Blood, 2016, 128, 961-961.	1.4	6
158	Isogenic iPSC Models of SRSF2-Mutant Myelodysplastic Syndrome Capture Disease Phenotypes, Splicing Defects and Drug Responses. Blood, 2016, 128, 962-962.	1.4	2
159	H3B-8800, an Orally Bioavailable Modulator of the SF3b Complex, Shows Efficacy in Spliceosome-Mutant Myeloid Malignancies. Blood, 2016, 128, 966-966.	1.4	27
160	Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. Oncotarget, 2016, 7, 85430-85436.	1.8	60
161	Melanoma and nonâ€melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30â€year experience at Memorial Sloan Kettering Cancer Center. British Journal of Haematology, 2015, 171, 84-90.	2.5	14
162	Hairy cell leukemia. Current Opinion in Hematology, 2015, 22, 355-361.	2.5	7

#	Article	IF	CITATIONS
163	Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing. ELife, 2015, 4, .	6.0	125
164	Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nature Medicine, 2015, 21, 1473-1480.	30.7	128
165	JAK–STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response. Cancer Discovery, 2015, 5, 316-331.	9.4	252
166	Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. Molecular Cell, 2015, 59, 345-358.	9.7	125
167	SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. Cancer Cell, 2015, 27, 617-630.	16.8	449
168	Loss of BAP1 function leads to EZH2-dependent transformation. Nature Medicine, 2015, 21, 1344-1349.	30.7	297
169	Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. New England Journal of Medicine, 2015, 373, 1733-1747.	27.0	281
170	BET inhibitor resistance emerges from leukaemia stem cells. Nature, 2015, 525, 538-542.	27.8	441
171	BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Cancer Cell, 2015, 28, 370-383.	16.8	392
172	Prospective Blinded Study of <i>BRAF</i> V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders. Cancer Discovery, 2015, 5, 64-71.	9.4	115
173	Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. Leukemia and Lymphoma, 2015, 56, 1938-1948.	1.3	6
174	Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. Journal of Clinical Investigation, 2015, 125, 1857-1872.	8.2	151
175	Collaborating constitutive and somatic genetic events in myeloid malignancies: ASXL1 mutations in patients with germline GATA2 mutations. Haematologica, 2014, 99, 201-203.	3.5	39
176	Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. Leukemia and Lymphoma, 2014, 55, 1968-1979.	1.3	23
177	Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5401-10.	7.1	238
178	DNA Hydroxymethylation Profiling Reveals that WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia. Cell Reports, 2014, 9, 1841-1855.	6.4	237
179	Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia. Molecular Cancer Therapeutics, 2014, 13, 1979-1990.	4.1	49
180	D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes and Development, 2014, 28, 479-490.	5.9	70

#	Article	IF	CITATIONS
181	Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood, 2014, 123, e123-e133.	1.4	337
182	Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies. Cancer Discovery, 2014, 4, 538-545.	9.4	73
183	Somatic alterations and dysregulation of epigenetic modifiers in cancers. Biochemical and Biophysical Research Communications, 2014, 455, 24-34.	2.1	29
184	Hematopoietic Stem Cell Origin of <i>BRAF</i> V600E Mutations in Hairy Cell Leukemia. Science Translational Medicine, 2014, 6, 238ra71.	12.4	102
185	Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. Blood, 2014, 124, 1445-1449.	1.4	105
186	Recent Discoveries in Molecular Characterization of Acute Myeloid Leukemia. Current Hematologic Malignancy Reports, 2014, 9, 93-99.	2.3	15
187	The mutational landscape of paroxysmal nocturnal hemoglobinuria revealed: new insights into clonal dominance. Journal of Clinical Investigation, 2014, 124, 4227-4230.	8.2	20
188	Femoral Bone Marrow Aspiration in Live Mice. Journal of Visualized Experiments, 2014, , .	0.3	12
189	Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood, 2014, 124, 483-492.	1.4	462
190	Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood, 2014, 124, 3016-3019.	1.4	197
191	Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms. Haematologica, 2014, 99, 797-801.	3.5	6
192	<i>BRAF</i> -mutant hematopoietic malignancies. Oncotarget, 2014, 5, 7980-7981.	1.8	3
193	Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood, 2013, 122, 893-901.	1.4	184
194	Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood, 2013, 121, 4917-4924.	1.4	175
195	Clinical and Pathologic Impact of Select Chromatin-modulating Tumor Suppressors in Clear Cell Renal Cell Carcinoma. European Urology, 2013, 63, 848-854.	1.9	198
196	Refining the prognostic importance of the diversity of <i>FLT3</i> internal tandem duplications. Leukemia and Lymphoma, 2013, 54, 3-4.	1.3	1
197	Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood, 2013, 121, 3563-3572.	1.4	218
198	Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. Leukemia Research, 2013, 37, 32-36.	0.8	29

#	Article	IF	CITATIONS
199	The Potential for Isocitrate Dehydrogenase Mutations to Produce 2-Hydroxyglutarate Depends on Allele Specificity and Subcellular Compartmentalization. Journal of Biological Chemistry, 2013, 288, 3804-3815.	3.4	141
200	Notch pathway activation targets AML-initiating cell homeostasis and differentiation. Journal of Experimental Medicine, 2013, 210, 301-319.	8.5	148
201	Regulation of c-Myc Ubiquitination Controls Chronic Myelogenous Leukemia Initiation and Progression. Cancer Cell, 2013, 23, 362-375.	16.8	111
202	Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemia. Nature Medicine, 2013, 19, 437-445.	30.7	202
203	EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation. Cancer Cell, 2013, 23, 677-692.	16.8	706
204	Focus on the epigenome in the myeloproliferative neoplasms. Hematology American Society of Hematology Education Program, 2013, 2013, 538-544.	2.5	11
205	Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica, 2013, 98, 591-596.	3.5	58
206	Importance of Genetics in the Clinical Management of Chronic Myelomonocytic Leukemia. Journal of Clinical Oncology, 2013, 31, 2374-2376.	1.6	9
207	HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders. Journal of Experimental Medicine, 2013, 210, 339-353.	8.5	41
208	2-Hydroxyglutarate in <i>IDH</i> mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. Leukemia and Lymphoma, 2013, 54, 408-410.	1.3	21
209	Translocation t(11;17) in de novo Myelodysplastic Syndrome Not Associated with Acute Myeloid or Acute Promyelocytic Leukemia. Acta Haematologica, 2013, 129, 48-54.	1.4	2
210	The ASXL–BAP1 axis: new factors in myelopoiesis, cancer and epigenetics. Leukemia, 2013, 27, 10-15.	7.2	78
211	Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. Journal of Experimental Medicine, 2013, 210, 2641-2659.	8.5	278
212	GM-CSF–dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood, 2013, 121, 5068-5077.	1.4	137
213	Detection of an NRAS mutation in Erdheim-Chester disease. Blood, 2013, 122, 1089-1091.	1.4	57
214	Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod,) Tj ETQq0 0 0 rgE	3T Qverloo 1.4	ck 10 Tf 50 1 104

215	The importance of subclonal genetic events in MDS. Blood, 2013, 122, 3550-3551.	1.4	11
216	Myelodysplastic syndromes are induced by histone methylationââ,¬â€œaltering ASXL1 mutations. Journal of Clinical Investigation, 2013, 123, 4627-4640.	8.2	140

#	Article	IF	CITATIONS
217	Identification Of Actionable Genomic Alterations In Hematologic Malignancies By a Clinical Next Generation Sequencing-Based Assay. Blood, 2013, 122, 230-230.	1.4	2
218	Molecular genetics of acute myeloid leukemia: clinical implications and opportunities for integrating genomics into clinical practice. Hematology, 2012, 17, s39-s42.	1.5	7
219	CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood, 2012, 120, 2297-2306.	1.4	92
220	Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes. Journal of Clinical Oncology, 2012, 30, 3376-3382.	1.6	419
221	Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nature Genetics, 2012, 44, 1179-1181.	21.4	692
222	ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression. Cancer Cell, 2012, 22, 180-193.	16.8	504
223	Role of TET2 and ASXL1 Mutations in the Pathogenesis of Myeloproliferative Neoplasms. Hematology/Oncology Clinics of North America, 2012, 26, 1053-1064.	2.2	28
224	Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment. New England Journal of Medicine, 2012, 367, 2316-2321.	27.0	222
225	The role of mutations in epigenetic regulators in myeloid malignancies. Nature Reviews Cancer, 2012, 12, 599-612.	28.4	614
226	Loss of the Tumor Suppressor BAP1 Causes Myeloid Transformation. Science, 2012, 337, 1541-1546.	12.6	355
227	Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leukemia Research, 2012, 36, 1500-1504.	0.8	47
228	Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia. New England Journal of Medicine, 2012, 366, 1079-1089.	27.0	1,688
229	Epigenetic alterations in hematopoietic malignancies. International Journal of Hematology, 2012, 96, 413-427.	1.6	48
230	Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature, 2012, 489, 155-159.	27.8	320
231	IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature, 2012, 483, 474-478.	27.8	1,693
232	Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood, 2012, 119, 4480-4485.	1.4	189
233	Mutations in Epigenetic Modifiers in Myeloid Malignancies and the Prospect of Novel Epigenetic-Targeted Therapy. Advances in Hematology, 2012, 2012, 1-12.	1.0	73
234	FISHing for TET2: Utility of FISH for TET2 deletions detection in clinical samples. Leukemia Research, 2012, 36, 25-26.	0.8	1

#	Article	IF	CITATIONS
235	Disordered Epigenetic Regulation in the Pathophysiology of Myeloproliferative Neoplasms. Current Hematologic Malignancy Reports, 2012, 7, 34-42.	2.3	7
236	Interpreting new molecular genetics in myelodysplastic syndromes. Hematology American Society of Hematology Education Program, 2012, 2012, 56-64.	2.5	26
237	Conditional Deletion of Asxl1 Results in Myelodysplasia. Blood, 2012, 120, 308-308.	1.4	0
238	Removal of Macrophages From the Erythroid Niche Impairs Stress Erythropoiesis but Improves Pathophysiology of Polycythemia Vera and Beta-Thalassemia. Blood, 2012, 120, 81-81.	1.4	0
239	Interpreting new molecular genetics in myelodysplastic syndromes. Hematology American Society of Hematology Education Program, 2012, 2012, 56-64.	2.5	14
240	Clinical Implications of Novel Mutations in Epigenetic Modifiers in AML. Hematology/Oncology Clinics of North America, 2011, 25, 1119-1133.	2.2	40
241	TET Family Proteins and Their Role in Stem Cell Differentiation and Transformation. Cell Stem Cell, 2011, 9, 193-204.	11.1	209
242	Genetics of the Myeloproliferative Neoplasms. , 2011, , 39-68.		0
243	Clinical Effect of Point Mutations in Myelodysplastic Syndromes. New England Journal of Medicine, 2011, 364, 2496-2506.	27.0	1,444
244	ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition. Haematologica, 2011, 96, 342-343.	3.5	24
245	Genetics of the myeloproliferative neoplasms. Current Opinion in Hematology, 2011, 18, 117-123.	2.5	44
246	Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell–stimulated T cells yet preserves immunity to recall antigen. Blood, 2011, 118, 5330-5339.	1.4	86
247	A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature, 2011, 473, 230-233.	27.8	351
248	JAK2V617F-Mediated Phosphorylation of PRMT5 Downregulates Its Methyltransferase Activity and Promotes Myeloproliferation. Cancer Cell, 2011, 19, 283-294.	16.8	225
249	Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation. Cancer Cell, 2011, 20, 11-24.	16.8	1,105
250	The Spliceosome as an Indicted Conspirator in Myeloid Malignancies. Cancer Cell, 2011, 20, 420-422.	16.8	35
251	Aberrant Epigenetic and Genetic Marks Are Seen in Myelodysplastic Leukocytes and Reveal Dock4 as a Candidate Pathogenic Gene on Chromosome 7q. Journal of Biological Chemistry, 2011, 286, 25211-25223.	3.4	41
252	Dynamics of Mutant Alleles in Patients with Advanced Essential Thrombocythemia (ET) or Polycythemia (PV) During Pegylated Interferon-Alfa-2A (PEG-IFN-α-2A; Pegasys) Therapy. Blood, 2011, 118, 281-281.	1.4	2

#	Article	IF	CITATIONS
253	Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms. American Journal of Hematology, 2010, 85, 81-83.	4.1	22
254	Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood, 2010, 115, 2919-2927.	1.4	72
255	Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: possible role in 20qâ° polycythemia vera. Blood, 2010, 116, 2812-2821.	1.4	51
256	The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate. Cancer Cell, 2010, 17, 225-234.	16.8	1,754
257	EZH2 Mutations: Mutating the Epigenetic Machinery in Myeloid Malignancies. Cancer Cell, 2010, 18, 105-107.	16.8	10
258	The Notch/Hes1 Pathway Sustains NF-κB Activation through CYLD Repression in T Cell Leukemia. Cancer Cell, 2010, 18, 268-281.	16.8	261
259	Leukemic IDH1 and IDH2 Mutations Result inÂa Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. Cancer Cell, 2010, 18, 553-567.	16.8	2,328
260	Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias. Cancer Research, 2010, 70, 447-452.	0.9	279
261	Metabolism and the leukemic stem cell. Journal of Experimental Medicine, 2010, 207, 677-680.	8.5	70
262	A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 17604-17609.	7.1	119
263	HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. Journal of Clinical Investigation, 2010, 120, 3578-3593.	8.2	162
264	High-Throughput Mutational Profiling In AML: Mutational Analysis of the ECOG E1900 Trial. Blood, 2010, 116, 851-851.	1.4	4
265	Recent advances in the treatment of acute myeloid leukemia. F1000 Medicine Reports, 2010, 2, 55.	2.9	12
266	JAK2V617F-Mediated Phosphorylation of PRMT5 Down-Regulates Its Methyltransferase Activity and Promotes Myeloproliferation. Blood, 2010, 116, 794-794.	1.4	0
267	Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood, 2009, 114, 144-147.	1.4	661